Rare Diseases: The Role of Social Media in Patient Recruitment
Since the passing of the Orphan Drug Act in 1983, the rate of drug development in the United States has seen a significant increase. The act directly impacted funding – a maj
Want More Cures? Modernize Clinical Trials
As the federal government creates a plan to speed the pace of drug development in the U.S., one specialty contract research organization suggests that a more modernized approach to
Lab Tools and Ancient Sea Life: Medicine’s Lust for a Crab’s Blood
In the pharmaceutical and biomedical industries, the horseshoe crab is nothing short of a celebrity. If you haven’t heard about this creature and its exceedingly valuable blue bl
2014 FDA Drug Approvals at 18-year High, but How Much New Ground Are We Breaking?
As the New Year bells chimed in 2015, the curtains drew shut on this century’s best year for novel-drug approvals. The U.S. FDA green-lighted 41 new agents for the U.S. market, i
What You Cared About in 2014
As the year closes, one can’t help but reflect. So, we take a look back at our most popular blog posts from 2014. During the last 12 months, Chempetitive Group’s blog published
The J.P. Morgan Healthcare Conference: Worth the Fuss?
Attendance is by invitation only. There’s no trade show floor. And, good luck tracking down information on speakers and schedules if you’re not invited — a public website for
Usability: Making Better Websites with Dead Simple User Experience
Let’s get something straight: We’re all marketing to humans. Yes, customers’ perspectives, experiences and industries may differ — even within the life sciences industry. B
Top 10 Biotech IPOs of 2014: West Coast Dominates
What was the most successful biotech IPO of 2014? Look no further than Ultragenyx. A special report by Fierce Biotech says that the Novato, Calif., maker of treatments for rare and
Replacing Adderall: Medicines to Change the World (Part I)
It’s a sad beginning to my series on medications set to change society and the way we live our lives. Shares in the promising biotech Alcobra Pharma plummeted 50 percent this wee
How to Overcome the Life Science Startup Blues
Life science entrepreneurs endure a lot of startup turmoil. First, they face all the usual challenges of understanding the market’s nuances, developing an airtight business model